Two new drugs appear to offer palliative relief from painful bone metastases associated with advanced prostate cancer, improving patients' quality of life (QOL) and slowing disease progression. Study data for the 2 drugs, atrasentan [ABT 627] and clodronic acid, were reported recently at the 37th Annual Meeting of the American Society of Clinical Oncology [San Francisco, US; May 2001].